Krü ppel-like factors (KLFs) as a family of zinc-finger transcription factors involve in the regulation of many physiological processes. In these studies, KLF9 was characterized for its role in adipogenesis. The expression of KLF9 was markedly upregulated during the middle stage of 3T3-L1 adipocyte differentiation, and inhibition of KLF9 by RNAi impaired adipogenesis. Using promoter deletion and mutation analysis, we identified two KLF9-binding sites within the 0.6-kb region of the PPARc2 proximal promoter, indicating that KLF9 interacts with the PPARc2 promoter. Furthermore, we found that KLF9 could synergistically activate PPARc2 promoter by directly interacting with C/EBPa. In addition, overexpression of PPARc2 rescued the impairment of adipocyte differentiation induced by KLF9 knockdown, which supports that PPARc2 is a downstream target of KLF9. Collectively, our results indicate KLF9 as a key pro-adipogenic transcription factor through regulation of PPARc2 expression with C/EBPa at the middle stage of adipogenesis.
Obesity is now a prevalent health hazard worldwide, which tends to develop a number of pathological disorders such as type-2 diabetes and cardiovascular disease. 1 This excess of adipose tissue can be the consequence of both increased fat-cell number (hyperplasia) and increased fat-cell size (hypertrophy). 2 The number of adipocytes present in an organism is determined to a large degree by the adipocyte differentiation process. Consequently, understanding the mechanisms regulating adipocyte differentiation may provide valuable information in limiting obesity and its pathological consequences. The 3T3-L1 cell line has been widely used as adipogenesis model to elucidate the mechanism of adipocyte differentiation, in which confluent 3T3-L1 pre-adipocytes differentiate into adipocytes upon exposure to a hormone cocktail including isobutylmethylxanthine, dexamethasone and insulin (MDI). 3, 4 A number of transcription factors are involved in the regulation of adipogenesis, including the peroxisome proliferator-activated receptor (PPAR) family [5] [6] [7] and CCAAT/ enhancer-binding proteins. 8, 9 PPARg is a member of the nuclear receptor superfamily, and is both necessary and sufficient for adipogenesis. 10 PPARg1 and PPARg2 are generated by alternative splicing and promoter usage and induced during adipogenesis. PPARg1 is found in other cell types besides adipocytes, whereas PPARg2 is expressed specifically in adipocytes. 11 In 3T3-L1 pre-adipocytes, a hormonal adipogenic stimulus induces a transient increase in the expression of C/EBPb and C/EBPd, 12 which then stimulates cell proliferation and expression of PPARg2 and C/EBPa. Once activated, PPARg2 and C/EBPa can crossregulate one another to maintain their expression and other adipogenic factors in mature adipocyte. 13 Krü ppel-like factors (KLFs) are members of an emerging family of DNA-binding transcriptional regulators with crucial roles in development, differentiation and a number of other physiological cellular processes. 14 The members of this protein family contain three C2H2 zinc fingers near their C-terminus, which recognize CACCC and related GC-rich elements in promoters and enhancers, and their N-terminal domains are highly variable and show different molecular functions. 14 Previous reports showed that KLF proteins had different expression patterns during adipogenesis and several KLFs had been proved to either promote or inhibit this process. [15] [16] [17] [18] [19] [20] [21] Krü ppel-like factor 9 (KLF9), previously designated as basic transcription element-binding protein-1 (BTEB1), was initially isolated from a rat liver cDNA library. 22 KLF9 was further identified to be important for development and other physiological functions. For example, female mice null for the Klf9 gene show some defects such as uterine growth retardation, fewer numbers of embryo implantation sites and decreased litter size. 23 KLF9 could control intestinal crypt cell proliferation and villus cell migration. 24 In addition, KLF9 is required for proper maturation of the central nervous system. 25 Furthermore, KLF9 may function at the node of progesterone receptor and estrogen receptor genomic pathways to influence cell proliferation. 26 In our previous study with mouse oligonucleotide microarray, it was identified that the expression of Klf9 was induced during 3T3-L1 adipocyte differentiation. In the present study, we found that KLF9 functioned in adipocyte differentiation through transactivating PPARg2.
Results
The expression of KLF9 increases at the middle stage of adipogenesis. To detect whether KLF9 was related to adipogenesis, we isolated rat primary pre-adipocytes and induced these cells for differentiation. Western blot analysis showed that the protein level of KLF9 was elevated in adipocytes, but undetectable in pre-adipocytes ( Figure 1a ). As expected, the expression levels of other adipocytespecific proteins such as PPARg and aP2 were also greatly increased in adipocytes 4 ( Figure 1a ). As 3T3-L1 pre-adipocytes have been widely used as an in vitro model for adipogenesis, we analyzed the expression of KLF9 during 3T3-L1 cell differentiation induced by the standard hormone cocktail MDI. 3, 4 Real-time PCR analysis showed that the KLF9 mRNA significantly increased from day 4 of the MDI induction, reaching a maximum at day 7 ( Figure 1b) . As expected, the mRNA levels of other adipogenesis-specific marker genes such as PPARg, C/EBPa, Adiponectin and aP2 also increased during the process of 3T3-L1 cell differentiation (Figure 1b) .
Furthermore, western blot analysis showed that the KLF9 protein was first clearly detected at day 4 after the MDI induction and continuously increased during the process of adipogenesis, whereas this protein was undetectable in 3T3-L1 preadipocytes ( Figure 1c ). The expression pattern of KLF9 was similar to that of previously reported later transcription factors for adipogenesis such as C/EBPa and PPARg, 27 but different from that of early transcription factors such as C/EBPb 12 ( Figure 1c ). In addition, the results determined by immunofluorescence staining and sub-cellular fractionation assays showed that KLF9 proteins mainly lied in the nucleus at day 4 of adipogenesis, whereas a portion of KLF9 proteins was detected in the cytosol fraction at day 8 ( Supplementary Figure 1) .
To find out if overexpression of KLF9 at the early stage had any effect on adipocyte differentiation, we forced exogenous KLF9 expression in 3T3-L1 pre-adipocytes, and then induced the cells for adipogenesis with MDI. The results showed that KLF9 overexpression at the early stage of adipogenesis did not upregulate the expression level of C/EBPa or PPARg (Supplementary Figure 2) . It was not sufficient for the initiation of adipogenesis.
KLF9 functions in adipogenesis at the middle stage of 3T3-L1 adipocyte differentiation. To address the function of KLF9 in adipogenesis, we established five stable cell lines containing different small interference RNA (siRNA) sequences against KLF9 (see Materials and Methods). The results showed that KLF9 was knocked down at both the mRNA and the protein level in these stable cell lines with or without the MDI induction (Figure 2a and b) . Importantly, the results determined by Oil-red-O staining assay indicated that KLF9 knockdown by RNA interference (RNAi) suppressed adipocyte differentiation (Figure 2c ), suggesting that KLF9 is essential for adipogenesis.
We further analyzed the expressions of adipocyte-specific markers in two KLF9-knockdown cell lines. Real-time PCR analysis showed that the mRNA expression levels of PPARg, C/EBPa and aP2 were inhibited in these cells (Figure 2d ). In agreement with the mRNA results, the western blot results indicated downregulation of these adipogenic protein markers (Figure 2e) . Conversely, the mRNA levels of early transcription factors of adipogenesis, including C/EBPb, C/EBPd, KLF5 and Krox20, did not show significant changes in these KLF9-knockdown cells, compared with that of the control cells (Supplementary Figure 3) , suggesting that KLF9 does not function at the early stage of adipogenesis. Taken together, these results indicate that KLF9 is required for adipocyte differentiation and the time frame of its function is at the middle stage of adipogenesis, which is in accordance with the expression pattern of KLF9 during the process of adipocyte differentiation ( Figure 1 ).
To find out if differences in C/EBPa and PPARg expression between the normal and KLF9-knockdown cell lines resulted from variations in mRNA stability, we analyzed the effects of KLF9 knockdown on the mRNA stability for PPARg and C/EBPa. As shown in Supplementary Figure 4 , there was no significant difference in the mRNA stability for PPARg and C/EBPa among the control and KLF9-knockdown cells, suggesting that downregulation of C/EBPa or PPARg mRNAs in the KLF9-knockdown cells results from transcriptional suppression rather than reduction of mRNA stability. KLF9 could transactivate PPARc2. As a transcription factor, what kind of target gene(s) KLF9 might regulate? As shown in Supplementary Figure 3 , downregulation of KLF9 did not affect the expression of early adipogenic factors. In addition, downregulation of KLF9 also did not influence the expression of some inhibitory factors such as DLK1, CHOP10, KLF2 or GATA2 11 (data not shown). In consideration of the time frame of its expression, we proposed three adipogenic transcription factors, C/EBPb, C/EBPa and PPARg2, as potential KLF9 targets during the process of adipogenesis. Bioinformatics analysis showed that each of the three promoters, including 3.0 kb of the C/EBPb promoter, 1.5 kb of the C/EBPa promoter and 3.2 kb of the PPARg2 promoter, had many potential binding sites for KLF9 (Figure 3a) .
To identify the KLF9-targeted promoter(s) from these three candidates, we co-transfected HEK293 cells with a plasmid expressing myc-tagged KLF9 protein and a luciferase reporter plasmid containing C/EBPa, or C/EBPb or PPARg2 promoters, respectively. The results showed that KLF9 could activate the PPARg2 promoter (Figure 3d) , whereas no such effect was detected on the promoters of C/EBPa or C/EBPb (Figure 3b and c), suggesting that PPARg2 was the downstream target of KLF9.
The small proximal promoter region of PPARc2 is sufficient for KLF9 binding and transactivating activity. To identify the PPARg2 promoter region responsible for KLF9 Figure 4b showed that 0.6-kb promoter of PPARg2 had similar activity as the 1.3-kb, or the 2.1-kb, and even the total 3.2-kb promoter in response to KLF9 activation in HEK293 cells, which was also confirmed in the NIH3T3 cell line (Supplementary Figure 5a) . These results suggest that the 0.6-kb proximal promoter region of PPARg2 is sufficient to drive the gene expression by KLF9.
Sequence analysis of the 0.6-Kb PPARg2 promoter predicted two possible KLF9-binding sites at À304 and To assess whether KLF9 could bind specifically to the PPARg2 promoter during adipogenesis, we analyzed the binding activity of KLF9 to the endogenous PPARg2 promoter in 3T3-L1 cells by chromatin immunoprecipitation (ChIP) assays (see Materials and Methods). ChIP results showed that significant KLF9 binding to the À413 to À247 region of the PPARg2 promoter was detected at day 4 after MDI induction ( Figure 5b , left panel; Supplementary Table S1). As positive control, C/EBPa binding to the same promoter region was detectable at day 4 and peaked at day 8 ( Figure 5b , left panel). As negative control, neither C/EBPa nor KLF9 could bind to the À2000-bp region of the PPARg2 promoter ( Figure 5b , right panel; Supplementary Table S1 ), which is in agreement with previous report that C/EBPa does not bind to the distal region of the PPARg2 promoter, 28 and our observation that KLF9 binds to the 0.6-kb proximal promoter region of PPARg2 (Figure 4 ). Taken together, the results indicate that KLF9 could directly bind to the promoter region of PPARg2 at the middle stage of 3T3-L1 adipocyte differentiation.
KLF9 acts in concert with C/EBPa to transactivate the PPARc2 promoter. We realized that KLF9 itself stimulated modest PPARg2 promoter activity in reporter assays (Figure 3d ), and KLF9 knockdown partially inhibited the expression of PPARg (Figure 2d ). These results imply that KLF9 might interact with other transcription factor(s) to synergistically activate PPARg2 like its family members, KLF5 18 and KLF15. 21 The result detected by the luciferase report assay showed that when KLF9 was co-transfected with C/EBPa, the two factors acted in concert to more strongly transactivate the PPARg2 promoter ( Figure 6a) .
Furthermore, the result of Oil-red-O staining at day 4 of MDI-induced adipocyte differentiation showed that inhibition of C/EBPa expression with a chemically synthetic siRNA oligo in the KLF9-knockdown cells impaired adipogenesis more significantly than that of the KLF9 knockdown (Ri-1) alone or C/EBPa-siRNA (si-348) alone ( Figure 6b and Supplementary Figure 6 ). In addition, the results of real-time PCR and western blot showed that PPARg expression was further inhibited when expression of C/EBPa was repressed in the KLF9-knockdown cells (Figure 6c and d) . Taken together, these results indicate that KLF9 should act in concert with C/EBPa to efficiently transactivate the PPARg2 promoter.
KLF9 physically interacts with C/EBPa. We further analyzed whether the synergistic activating effect of KLF9 and C/EBPa on the PPARg2 promoter was due to physical interaction between these two proteins. We ectopically expressed KLF9 and C/EBPa in HEK293 cells and then detected the proteins by co-immunoprecipitation assays. The results showed there might be a physical interaction between KLF9 and C/EBPa (Figure 7a ). To further confirm this observation, we purified the fusion proteins GST-KLF9 and GST-C/EBPa, and then incubated these two proteins with lysates of HEK293 cells overexpressing C/EBPa or KLF9, respectively (see Materials and Methods). The results detected by GST pull-down assay showed that the C/EBPa proteins in the cell lysate could be pulled down in the presence of the GST-KLF9 proteins (Figure 7b , left panel), whereas KLF9 in the cell lysate could be pulled down in the presence of GST-C/EBPa (Figure 7b, right panel) . Taken together, these results indicate there is physical interaction between KLF9 and C/EBPa.
To further identify the local region(s) of KLF9 responsible for its interaction with C/EBPa, we constructed six GST-fused truncated fragments of KLF9, which were subjected to GST pull-down analysis. The results showed that the C/EBPa-interaction domain of KLF9 lied in the region from amino acid 143 to 225 (Figure 7c) . Conversely, to identify the C/EBPa domain interacting with KLF9, we constructed two GST-fused truncated fragments of C/EBPa and then applied the same GST pull-down assay. The results showed that the C/EBPa domain responsible for interaction with KLF9 localized between amino acid 1 and 110 of C/EBPa (Figure 7d ).
Ectopic expression of PPARc2 rescues the impairment of adipogenesis in KLF9-knockdown 3T3-L1 cells. As these results indicate that KLF9 transactivates PPARg2, we expected that overexpression of PPARg2 could reverse the defect in adipogenesis due to KLF9 deficiency. To test this hypothesis, we infected the stable cell line of KLF9 knockdown with a retrovirus encoding PPARg2. Real-time PCR assay confirmed both siRNA-mediated knockdown of endogenous KLF9 expression and ectopic expression of PPARg2 in this cell line (Figure 8a) , and western blot analysis showed overexpression of PPARg2 before (day 0) and after (day 8) MDI induction (Figure 8b ). These cells were subjected to adipocyte differentiation and detected by Oil-red-O staining assay. The results showed that ectopic PPARg2 expression rescued the impairment of adipogenesis caused by KLF9 knockdown (Figure 8c) . Furthermore, real-time PCR analysis showed that the mRNA levels of PPARg, C/EBPa and aP2 in these KLF9-knockdown cells expressing ectopic PPARg2 were recovered (Figure 8d ). In agreement with the mRNA results, the western blot results indicated recovery of protein levels of these adipogenic markers (Figure 8e) . Collectively, these results support the conclusion that KLF9 involves in adipogenesis regulation by transactivating PPARg2.
Discussion
The dynamic changes of the sub-cellular localization and activities of KLF9 during the process of 3T3-L1 adipocyte differentiation. In this study, we showed that KLF9 expression at both the mRNA and protein level continuously increased during adipocyte differentiation (Figure 1b and c) , whereas expression of PPARg increased from day 2 to day 6 (Figure 1b) , indicating that the expression pattern of KLF9 and PPARg during the differentiation is not completely parallel. This phenomenon could be explained as follows: First, we showed that KLF9 acted in concert with C/EBPa to more strongly transactivate the PPARg2 promoter (Figure 6a ). In fact, the expression profile of C/EBPa is quite similar to that of PPARg (Figure 1b) . Secondly, although KLF9 protein level was much higher at day 8 than that at day 4 during the MDI-induced differentiation, KLF9 no longer bound to the PPARg2 promoter, as shown by ChIP (Figure 5b) , and a great part of KLF9 existed in the cytoplasm, as shown by immunofluorescence and sub-cellular fractionation analysis (Supplementary Figure 1) . We speculate that post-translational modifications might be involved in KLF9's sub-cellular localization and function. Posttranslational modifications are widely used by transcription factors to regulate their sub-cellular localizations and activities. 29 Several KLFs were reported to be phosphorylated and their transcriptional activities were changed by the modifications. [30] [31] [32] We found that when several serines on the KLF9 protein were mutated to alanines, its transcriptional activities detected by luciferase report assay for the PPARg2 promoter were greatly enhanced (unpublished data). However, whether post-translational modifications really happened to endogenous KLF9 in adipogenesis needs to be further investigated.
The relationship between KLF9 and other transcription factors for binding to the PPARc2 promoter. Downregulation of KLF9 by retrovirus-mediated RNAi impaired adipocyte differentiation, indicating that KLF9 is required for this process. However, ectopic KLF9 overexpression in 3T3-L1 pre-adipocytes had no obvious promotions on PPARg or C/EBPa expression at the early stages of differentiation (Supplementary Figure 2) . Our results are in agreement with a previous report that KLF9 overexpression does not lead to lipid accumulation in NIH3T3 cells. 21 The results from KLF9 overexpression and knockdown assays suggest that KLF9 is required but not sufficient to perform a full program of adipocyte differentiation.
The present works showed that KLF9 transactivated PPARg2 at the middle stage of adipocyte differentiation by directly binding to the PPARg2 promoter ( Figure 5 ). However, overexpression of KLF9 in 3T3-L1 pre-adipocytes did not lead to upregulation of PPARg at the early stage of differentiation (Supplementary Figure 2) , which suggests that the time of KLF9 upregulation is important for its function. We speculate that the cellular environment such as the expression levels of other transcription factors might be important for KLF9's function. Because of the high similarity in their DNA-binding zinc fingers, many KLFs bind to very similar consensus sites, such as CACCC boxes.
14 In fact, it is widely reported that different members of the KLF family may compete for the consensus sites of the promoter regions, perhaps due to similarity in their recognition sequences. [33] [34] [35] [36] [37] For example, KLF5 could abrogate the activating effect of KLF4 on the Klf4 promoter, whereas KLF4 could abrogate the inhibiting effect of KLF5 on the same promoter, and it was speculated that this competing effect was due to physical competition of the two proteins for binding to a cognate DNA sequence. 36 In another report, KLF9 competed with Sp1 for the BTE sequence in the cytochrome P4501A1 promoter. 34 Importantly, a previous work identified that KLF2 bound to a GC box at the proximal region of the PPARg2 promoter in preadipocytes and at the early stage of differentiation, 15 which is just the KLF9-binding site-II identified in the present experiment (Figures 4 and 5) . Thus, it is reasonable to speculate that the endogenous KLF2 binds to this specific region on the PPARg2 promoter in pre-adipocytes, which made the PPARg2 promoter unavailable for the ectopic KLF9 proteins. To test this possibility, we performed an in vitro competition transactivation assay for KLF9 and KLF2. As shown in Figure 3 and Supplementary Figure 7 , KLF9 itself modestly upregulated transcription from the PPARg2 promoter. This effect could be counteracted by expression of KLF2, and the inhibitory efficiency depends on the extent of KLF2 expression, which indicates that KLF2 and KLF9 compete for the same binding site on the PPARg2 promoter. We noticed that a small quantity of KLF2 was enough to abolish KLF9's transactivating activity to basal level, and KLF2's repression effects on PPARg2 promoter could hardly be reversed by increasing amounts of KLF9 (Supplementary Figure 7) , which indicates that the binding affinity of KLF2 to the PPARg2 promoter is higher than that of KLF9. So, it is reasonable to speculate that the exogenous KLF9 in pre-adipocytes may not be able to replace the endogenous KLF2, which already exists on the PPARg2 promoter. In addition, other inhibitory factors existing on the PPARg2 promoter before differentiation could also impede KLF9 to bind to the promoter. 38 For example, GATA2 and GATA3 are two transcription factors, which are abundant in pre-adipocytes and their expressions decline after differentiation. 38 Both proteins were reported to bind to the PPARg2 promoter and their binding site was just 13 bp upstream from the KLF9's binding site-II, which may also impede KLF9's binding. 38 The roles and relationships among the members of the KLF family during adipogenesis. Our present results and previous works have shown that four members of the KLF family have roles in adipocyte differentiation by regulating PPARg2 transcription. 15, 18, 21 These KLFs are expressed sequentially during adipogenesis. KLF2 is first expressed in 3T3-L1 pre-adipocytes and its expression is shut down after differentiation. 15 Then, KLF5 is induced 4 h after MDI induction and its expression peaks at the early stage of adipocyte differentiation. 18 The expression of KLF9 appears at the middle stage of differentiation and gradually increases throughout the middle and late stages (Figure 1 ). In addition, KLF15's expression pattern mimics KLF9 and is highly expressed in mature adipocytes. 21 These KLFs carry out their respective functions by binding to the PPARg2 promoter either to open up or to shut down its transcription. While the time frame for each KLF binding is different, the DNA elements they bind to are the same. These KLFs bind to one or both of the DNA elements within the 0.6-kb PPARg2 upstream promoter region, 15, 18 except for KLF15, whose binding target on PPARg2 promoter has not been identified. 21 We also found that KLF9 and C/EBPa have physical interactions and they can synergistically activate the PPARg2 promoter (Figure 6 and 7) . This observation is coincident with previous reports that KLF5 and C/EBPb/d interact directly and they colocalize on the PPARg2 promoter on day 2.5 of differentiation, 18 and KLF15 cooperates with C/EBPa to synergistically activate the PPARg2 promoter at the late stages. 21 Synergistic activation of the PPARg2 promoter by these factors and their physical interactions suggest that these molecules may form an enhanceosome, 18, 39, 40 and different enhanceosomes are formed at different stages.
Obesity has been closely related to a series of human health problems such as diabetes. Adipocyte differentiation is one of the direct causes of adipose formation in vivo. 41 Our finding adds a new member of the KLF family related to adipocyte differentiation and places KLF9 into a group of key pro-adipogenic transcription factors. The dissection of the mechanisms controlling KLF9 expression could lead to further identification of the mechanism that control adipogenesis, which would provide new clues against the growing incidence of obesity in the modern world. Primary pre-adipocyte isolation, culture and differentiation. Rat (normal male Sprague-Dawley rat) white adipose tissues from the epididymal, inguinal, omental and scapular fat pads were isolated and washed with PBS. The adipose tissues were then minced and digested with collagenase solution (1 mg/ml collagenase type-I, 2% BSA in PBS) for 1 h. The digested tissues were centrifuged at 200 g for 10 min. The floating fractions consisting of adipocytes were discarded and the pellets were then resuspended in erythrocyte lysis buffer (154 mM NH 4 Cl, 10 mM KHCO 3 , 0.1 mM EDTA) for 10 min to remove red blood cells. The suspension was filtered through a size 200 filter and the cells were pelleted by 200 g, 10 min centrifugation. The cells were resuspended in Dulbecco's modified Eagle's medium (DMEM)/F12 and the medium was changed 3 h after inoculation. Two days after inoculation, cells were induced to differentiate with 1 mg/ml insulin, 1 mM dexamethasone and 0.5 mM 1-methyl-3-isobutylxanthine. The medium was replaced with a medium containing 1 mg/ml insulin after 72 h, and then changed every other day.
3T3-L1 cell culture, differentiation induction and Oil-red-O staining. 3T3-L1 pre-adipocytes were cultured in DMEM supplemented with 10% calf serum (Invitrogen, Carlsbad, CA, USA). The 2-day post-confluent cells were induced for adipocyte differentiation following the protocol described previously. 42 Cytoplasmic triglyceride droplets were visible by day 4. The differentiated 3T3-L1 adipocyte monolayer was stained with Oil-red-O. 42 The Oilred-O in triglyceride droplets was extracted with 100% isopropanol and OD 510 nm was determined.
KLF9 knockdown and PPARc2 expression. For stable KLF9-knockdown cells, a retrovirus-based siRNA expression system was used. The targeted sequences of KLF9 were Ri-1, 5 0 -GTGGGAAAGTCTATGGAAA-3'; Ri-2, 5 0 -GGAGAGTCCCGATGAGGAT-3'; Ri-3, 5 0 -AGCCCATTACAGAGTGCAT-3'; Ri-4, 5 0 -GATTATTGCACGCTGGTCA-3' and Ri-5, 5 0 -GAGAAGAGATTCATGAGGA-3', and cloned into a pSIREN-Retro-Q Vector and shuttled into Knockout RNAi Systems (Clontech Laboratories Inc., Otsu, Shiga, Japan). A sequence of Shuffle, 5 0 -AA CTAGAGCCACAACTACC-3', was used as control. The retrovirus was produced in HEK293 cell following the manufacturer's protocol and infected the proliferating 3T3-L1 cells. The stable cell lines were selected in medium supplemented with 5 mg/ml puromycin.
For PPARg2 expression in KLF9-knockdown cells, mouse PPARg2 cDNA was cloned into a Clontech pMSCV/Hygro retrovirus expression system. The stable KLF9-knockdown cells were infected with a PPARg2 expression retrovirus and cultured in medium supplemented with 300 mg/ml hygromycin.
Real-time quantitative PCR. Total RNA of 3T3-L1 cells was isolated using the TRIzol Reagent (Invitrogen) and reverse transcribed according to the manufacturer's protocol (Takara, Dalian, China). The SYBR Green quantitative PCR analysis reactions (TOYOBO, Osaka, Japan) were then performed using the ABI Prism 7500 sequence detection system (Life Technologies Corporation, Carlsbad, CA, USA).
Luciferase assay for promoter activities. HEK293 cells or NIH3T3 cells were plated in a 24-well plate and transfected with the promoter-luciferase reporter plasmids using lipofectamine 2000 (Invitrogen). The cells were harvested 48 h after transfection and luciferase activity was measured using the Promega (Madison, WI, USA) Dual-Luciferase Reporter Assay System. Promoter activity was expressed as arbitrary luciferase units (firefly/renilla).
Immunoprecipitation and western blotting. For immunoprecipitation, HEK293 cells transfected with plasmids expressing the targeted proteins for 48 h, and then were lysed in buffer containing 1% Triton X-100, 50 mM Tris-Cl (pH 7.4), 120 mM NaCl and protease inhibitors (cocktail; Sigma). The cell debris was removed by centrifugation at 14 000 g for 15 min at 41C. The supernatant was collected and immunoprecipitated with appropriate primary antibodies. 43 Control goat or rabbit IgG was used as the negative control (Santa Cruz Biotechnology). The immunoprecipitated samples were subjected to western blot analysis. 43 GST fusion protein expression, purification and GST pull down. GST and GST fusion proteins were expressed in Escherichia coli BL21 (DE3) cells (Stratagene, Agilent Technologies, Inc., Santa Clara, CA, USA) and purified using a glutathione Sepharose 4B column (Amersham Biosciences Biotech Inc., Piscataway, NJ, USA). Purified GST or GST-fusion proteins were incubated with glutathione-Sepharose 4B beads in PBS at 41C for 2 h. After that, the beads were washed three times with PBS and then incubated with the HEK293 cell lysate at 41C overnight. Then the beads were collected by centrifugation and washed four times with the lysis buffer. The samples were then subjected to SDS-PAGE followed by western blot analysis with the indicated antibody.
Electrophoretic mobility-shift assay. The myc-tagged KLF9 GST fusion protein was incubated with two oligonucleotides corresponding respectively to two potential binding sites of KLF9 in the 0.6-kb promoter of the PPARg2 gene (site-I from À310 to À286: 5 0 -TGTACAGTTCACGCCCCTCACAGAA-3 0 and site-II from À128 to À104: 5 0 -GTGTTTATTCCCACCTCTCCCAAAT-3 0 ). Two mutated oligonucleotides were also used (mutI: 5 0 -TGTACAGTTACAGCCCCTCACAGAA-3 0 and mutII: 5 0 -GTGTTTATTCACAACTCTCCCAAAT-3 0 ) (potential KLF9-binding core sequences are indicated in bold and mutated nucleotides are underlined). Biotin labeling of probes was performed using the biotin 3 0 -end DNA-labeling kit (Thermo Fisher Scientific Inc., Rockford, IL, USA) according to the manufacturer's instructions. Single-stranded oligos were labeled individually and annealed for 1 h at 251C to produce double-stranded probes. A 2-mg weight of the myc-tagged KLF9 GST fusion protein was incubated at 251C with the binding buffer (Thermo) for 20 min. Then biotin 3 0 -end-labeled DNA probes were added. For specific or nonspecific competition or antibody supershift, the respective unlabeled DNA probes (100-fold excess) or antibody (1 mg control mouse IgG (Santa Cruz) or anti-myc 9E10 (Sigma)) were added to the reaction mixture before addition of labeled probes. Free probe and protein-DNA complexes were separated on 6% neutral polyacrylamide gel and transferred to a nylon membrane for detection using the Lightshift electrophoretic mobility shift assay kit (Thermo).
ChIP assay. ChIP assays were performed using a commercial kit according to the manufacturer's instructions (Upstate Biotechnologies Inc., Temecula, CA, USA). Chromatin samples were prepared from 3T3-L1 cells at the indicated time points after induction of adipocyte differentiation, and then immunoprecipitated with antibodies. Briefly, 2 Â 10 6 3T3-L1 cells at the indicated day of differentiation were cross-linked with 1% formaldehyde for 10 min at 371C, followed by cell lysis and sonication. Then proteins cross-linked with DNA were immunoprecipitated with 1 mg of anti-KLF9 antibody (C-17X; Santa Cruz) or anti-C/EBPa antibodies (14AA; Santa Cruz) and 40 ml of salmon sperm DNA/protein-A-agarose beads. The protein-Aagarose antibody-protein complexes were washed extensively and eluted, according to the manufacturer's recommendations. The cross-link was reversed and proteins were digested by proteinase-K for 1 h at 451C. DNA was recovered by phenol/chloroform extraction and ethanol precipitation, and used as template for PCR.
